Longeveron Inc
Change company Symbol lookup
Select an option...
LGVN Longeveron Inc
IVV iShares Core S&P 500 ETF
PKLBF Perk Labs Inc
LZ LegalZoom.com Inc
MTH Meritage Homes Corp
AAPL Apple Inc
GDL-C GDL Fund
NVDA NVIDIA Corp
NHYDY Norsk Hydro ASA
A Agilent Technologies Inc
Go

Health Care : Biotechnology |
Company profile

Longeveron Inc., formerly Longeveron LLC, is a clinical stage biotechnology company. The Company is focused on developing cellular therapies for specific aging-related and life-threatening conditions. Its lead investigational product is the LOMECEL-B cell-based therapy product (Lomecel-B), which is derived from culture-expanded medicinal signaling cells (MSCs) that are sourced from bone marrow of young healthy adult donors. It is sponsoring clinical trials in various indications, including Aging Frailty, Alzheimer's disease (AD), the Metabolic Syndrome, Acute Respiratory Distress Syndrome (ARDS) and hypoplastic left heart syndrome (HLHS). It is developing Lomecel-B as a therapy for Aging Frailty and is being designed to reduce inflammation associated with Aging Frailty and to promote an anti-inflammatory state by releasing anti-inflammatory molecules, which can promote physiological restoration to a more normal state. It is conducting two multicenter trials in the United States (U.S.)

Price
Delayed
$29.14
Day's Change
-1.53 (-4.99%)
Bid
--
Ask
--
B/A Size
--
Day's High
35.75
Day's Low
25.36
Volume
(Light)

Today's volume of 12,402,310 shares is on pace to be much lighter than LGVN's 10-day average volume of 65,603,538 shares.

12,402,310

Earnings information for LGVN is not available.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Information provided by Copyright © 2021. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.